Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials

Table 5 Subgroup analysis for the effect of statin therapy on stoke

Subgroup	Value	Reference	Statin	Control	Relative risk (95% CI)	p value	Heterogeneity	p value for heterogeneity
			(Event/total)	(Event/total)
Mean Age	> = 60	29,33,34	50/2768	72/2789	0.71[0.50,1.01]	0.058	0%	0.732
	<60	24	7/433	4/431	1.74[0.51,5.91]	0.373	-	-
Cardiovascular History	Yes	29,34	40/1130	58/1160	0.71[0.48,1.05]	0.088	0%	0.429
	No	26	37/3533	57/3663	0.67[0.45,1.02]	0.059	-	-
Baseline GFR	> = 60	26	37/3533	57/3663	0.67[0.45,1.02]	0.059	-	-
	<60	29,33	21/1924	26/1922	0.82[0.46,1.45]	0.488	0%	0.63
Baseline Creatinine	> = 1.5	29	11/286	12/293	0.94[0.42,2.09]	0.878
	<1.5	24,34	36/1277	50/1298	0.90[0.36,2.23]	0.815	54.9%	0.14
Baseline LDL Cholesterol	> = 3.0	24,29,34	47/1563	62/1591	0.82[0.51,1.30]	0.387	20.3%	0.29
	<3.0	33	10/1638	14/1429	0.71[0.32,1.60]	0.407	-	-
LDL Cholesterol Lowering	> = 30%	29,33	21/1924	26/1922	0.82[0.46,1.45]	0.488	0%	0.63
	<30%	24,26	44/3966	61/4094	0.90[0.38,2.14]	0.818	52.2%	0.15
Follow-up time	> = 3	24,26,29,34	84/5096	119/5254	0.73[0.55,0.96]	0.023	0%	0.43
	<3	33	10/1638	14/1629	0.71[0.32,1.59]	0.407	-	-

Abbreviations: CI confidential interval, GFR glomerular filtration rate, LDL low density lipoprotein.

ISSN: 1471-2261